4 completed, 2 recruiting, 1 terminated. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Recruiting 2, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow prexasertib: new trials by email Literature Review of prexasertib trials Research Report on prexasertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC Gemcitabine, ACR-368 - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 43 | 2024-09-25 | 2025-10-20 |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma ACR-368, Gemcitabine, OncoSignature - Endometrial Adenocarcinoma | Phase 2 | Recruiting | Acrivon Therapeutics | 350 | 2022-08-29 | 2026-08-21 |
| A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma Prexasertib, Irinotecan - Desmoplastic Small Round Cell Tumor, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 21 | 2019-09-17 | 2025-02-20 |
| A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer Prexasertib - Ovarian Cancer | Phase 2 | Completed | Eli Lilly and Company | 172 | 2018-04-10 | 2022-08-19 |
| A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency LY2606368 - Advanced Cancers | Phase 2 | Completed | Dana-Farber Cancer Institute | 27 | 2016-10-12 | 2022-10-21 |
| A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Prexasertib - Small Cell Lung Cancer | Phase 2 | Completed | Eli Lilly and Company | 133 | 2016-05-11 | 2020-03-17 |
| A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer LY2606368 - Ovarian Cancer, Breast Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 111 | 2015-01-20 | 2022-09-10 |
Ovarian Neoplasms (2) · Breast Neoplasms (1) · Desmoplastic Small Round Cell Tumor (1) · Endometrial Neoplasms (1) · Fanconi Anemia (1) · Hereditary Breast and Ovarian Cancer Syndrome (1) · Prostatic Neoplasms (1) · Rhabdomyosarcoma (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
Eli Lilly and Company (2) · Acrivon Therapeutics (1) · Dana-Farber Cancer Institute (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Memorial Sloan Kettering Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (7) · Spain (3) · France (2) · Germany (2) · Italy (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Greece (1) · Israel (1) · Netherlands (1) · Turkey (Türkiye) (1) · Ukraine (1)
Christine Chung, MD (1) · Emily Slotkin, MD (1) · Geoffrey Shapiro, MD, PhD (1) · Isabelle Ray-Coquard, MD (1) · Jung-Min Lee, M.D. (1) · Panagiotis Konstantinopoulos, MD (1)
PMID 34665631, PMID 29361470, PMID 36192237
2015 (1), 2017 (1)